Neuroactive steroids and seizure susceptibility

Epilepsy Research

Volumn 44, Issue 2-3, 2001, Pages 141-153

  Beyenburg, Stefan ^a   Stoffel Wagner, Birgit ^a   Bauer, Jürgen ^a   Watzka, Matthias ^a   Blümcke, Ingmar ^a   Bidlingmaier, Frank ^a   Elger, Christian E ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Epilepsy; Neuroactive steroids; Neuronal excitability; Neurosteroids; Seizures

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID RECEPTOR; ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; CORTICOSTEROID; ESTROGEN; GLUCOCORTICOID; MEMBRANE RECEPTOR; MESSENGER RNA; MINERALOCORTICOID; PREGNENOLONE; PROGESTERONE; PROGESTERONE RECEPTOR; TESTOSTERONE; TRIPTORELIN;

ALLOSTERISM; ARTICLE; BINDING SITE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EPILEPSY; GENE EXPRESSION REGULATION; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEIZURE; SEIZURE SUSCEPTIBILITY; STEROIDOGENESIS;

ADRENAL CORTEX HORMONES; ANIMALS; BRAIN; BRAIN DISEASES; EPILEPSY; ESTROGENS; GENE EXPRESSION; GONADAL STEROID HORMONES; HUMANS; PROGESTERONE; RECEPTORS, GABA-A; STEROIDS;

EID: 0035022721     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(01)00194-2     Document Type: Article

References (119)

1. Bäckström T., Rosciszewska D. Effects of hormones on seizure expression. Engel J. Jr, Pedley T.A. Epilepsy: A Comprehensive Textbook. 1997;2003-2012 Lippincott Raven, Philadelphia.
2. Bäckström T., Zetterlund B., Blom S., Romano M. Effects of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy. Acta Neurol. Scand. 69:1984;240-248.
3. Bäckström T., Gee K.W., Lan N., Sörensen M., Wahlström G. Steroids in relationship to epilepsy and anaesthesia. Chadwick D., Widdows K. Steroids and Neuronal Activity. 1990;225-239 Wiley, Chichester, UK. Ciba Foundation Symposium 153.
4. Bauer J., Wildt L., Flügel D., Stefan H. The effect of a synthetic GnRH analogue on catamenial epilepsy: a study in ten patients. J. Neurol. 239:1992;284-286.
5. Bauer J., Hocke A., Elger C.E. Catamenial seizures: an analysis (in German). Nervenarzt. 66:1995;760-769.
6. Bauer J., Burr W., Elger C.E. Seizure occurrence during ovulatory and anovulatory cycles in patients with temporal lobe epilepsy: a prospective study. Eur. J. Neurol. 5:1998;83-88.
7. Baulieu E.E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology. 23:1998;963-987.
8. Behl C., Holsboer F. The female sex hormone oestrogen as a neuroprotectant. Trends Pharmacol. Sci. 20:1999;441-444.
9. Belelli D., Lan N.C., Gee K.W. Anticonvulsant steroids and the GABA/benzodiazepine receptor-chloride-ionophore complex. Neurosci. Biobehav. Rev. 14:1990;315-322.
10. Bergeron R., de Montigny C., Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J. Neurosci. 16:1996;1193-1202.
11. Beyenburg S., Stoffel-Wagner B., Watzka M., Blümcke I., Bauer J., Schramm J., Bidlingmaier F., Elger C.E. Expression of cytochrome P450scc mRNA in the hippocampus of patients with temporal lobe epilepsy. NeuroReport. 10:1999;3067-3070.
12. Beyenburg S., Watzka M., Blümcke I., Schramm J., Bidlingmaier F., Elger C.E., Stoffel-Wagner B. Expression of mRNAs encoding for 17β-hydroxisteroid dehydrogenase isozymes 1, 2, 3, and 4 in epileptic human hippocampus. Epilepsy Res. 41:2000a;83-91.
13. Beyenburg S., Watzka M., Clusmann H., Blümcke I., Bidlingmaier F., Elger C.E., Stoffel-Wagner B. Androgen receptor mRNA expression in the human hippocampus. Neurosci. Lett. 294:2000b;25-28.
14. Bixo M., Andersson A., Winblad B., Purdy R.H., Bäckström T. Progesterone, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 764:1997;173-178.
15. Britton K.T., Koob G.F. Premenstrual steroids? Nature. 392:1998;869-870.
16. Brooks-Kayal A.R., Shumate M.D., Jin H., Rikhter T.Y., Coulter D.A. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat. Med. 4:1998;1166-1172.
17. A receptor. J. Pharmacol. Exp. Ther. 280:1997;1284-1295.
18. Chapman A.G. Glutamate and epilepsy. J. Nutr. 130:(4):2000;1043S-1045.
19. Duncan S., Read C.L., Brodie M.J. How common is catamenial epilepsy? Epilepsia. 34:1993;827-831.
20. During M.J., Ryder K.M., Spencer D.D. Hippocampal GABA transporter function in temporal lobe epilepsy. Nature. 376:1995;174-177.
21. Edwards H.E., Burnham W.M., Mendonca A., Bowlby D.A., MacLusky N.J. Steroid hormones affect limbic afterdischarge thresholds and kindling rates in adult female rats. Brain Res. 838:1999a;136-150.
22. Edwards H.E., Burnham W.M., MacLusky N.J. Testosterone and its metabolites affect afterdischarge thresholds and the development of amygdala kindled seizures. Brain Res. 838:1999b;151-157.
23. Frye C.A. The neurosteroid 3α, 5α-THP has antiseizure and possible neuroprotective effects in an animal model of epilepsy. Brain Res. 696:1995;113-120.
24. Frye C.A., Reed T.A. Androgenic neurosteroids: anti-seizure effects in an animal model of epilepsy. Psychoneuroendocrinology. 23:1998;385-399.
25. Gasior M., Carter R.B., Goldberg S.R., Witkin J.M. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. J. Pharmacol. Exp. Ther. 282:1997;543-553.
26. Gasior M., Carter R.B., Witkin J.M. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol. Sci. 20:1999;107-112.
27. Gasior M., Ungard J.T., Beekman M., Carter R.B., Witkin J.M. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure kindled-mice: comparison with diazepam and valproate. Neuropharmacology. 39:2000;1184-1196.
28. A receptor complex: the pharmacological properties and therapeutic potential of epalons. Crit. Rev. Neurobiol. 9:1995;207-227.
29. Grazzini E., Guillon G., Mouillac B., Zingg H.H. Inhibition of oxytocin receptor function by direct binding of progesterone. Nature. 392:1998;509-512.
30. Green C.J., Halsey M.J., Precious S., Wardley-Smith B. Alphaxolone-alphadolone anaesthesia in laboratory animals. Lab. Anim. 12:1978;85-89.
31. Haider Y., Barnett D.B. Catamenial epilepsy and gosorelin (letter). Lancet. 338:1991;1530.
32. Hammond G.L., Hirvonen J., Vihko R. Progesterone, androstene-dione, testosterone, 5α-dihydrotestosterone and androsterone concentrations in specific regions of the human brain. J. Ster. Biochem. 18:1983;185-189.
33. Herkes G.K., Eadie M.J., Sharbrough F., Moyer T. Patterns of seizure occurrence in catamenial epilepsy. Epilepsy Res. 15:1993;47-52.
34. Herzog A.G. Intermittent progesterone therapy and frequency of complex partial seizures in women with menstrual disorders. Neurology. 36:1986;1607-1610.
35. Herzog A.G. Clomiphene therapy in epileptic women with menstrual disorders. Neurology. 38:1988;432-434.
36. Herzog A.G. Reproductive endocrine considerations and hormonal therapy in men with epilepsy. Epilepsia. 32:(6):1991;S34-S37.
37. Herzog A.G. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology. 45:1995;1660-1662.
38. Herzog A.G. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology. 52:1999a;1917-1918.
39. Herzog A.G. Psychoneuroendocrine aspects of temporolimbic epilepsy. Part I. Brain, reproductive steroids, and emotions. Psychosomatics. 40:1999b;95-101.
40. Herzog A.G. Psychoneuroendocrine aspects of temporolimbic epilepsy. Part II. Epilepsy and reproductive steroids. Psychosomatics. 40:1999c;102-108.
41. Herzog A.G., Klein P., Ransil B.J. Three patterns of catamenial epilepsy. Epilepsia. 38:1997;1082-1088.
42. Herzog A.G., Klein P., Jacobs A.R. Testosterone versus testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism. Neurology. 50:1998;782-784.
43. Heuser E., Eidelberg E. Steroid-induced convulsions in experimental animals. Endocrinology. 69:1961;915-924.
44. Joels M. Steroid hormones and excitability in the mammalian brain. Front. Neuroendocrinol. 18:1997;2-48.
45. Joels M., de Kloet E.R. Mineralocorticoid receptor-mediated changes in membrane properties of rat CA1 pyramidal neurons in vitro. Proc. Natl. Acad. Sci. USA. 87:1990;4495-4498.
46. Joels M., Vreugdenhil E. Corticosteroids in the brain. Cellular and molecular actions. Mol. Neurobiol. 17:1998;87-108.
47. Karst H., de Kloet E.R., Joels M. Episodic corticosterone treatment accelerates kindling epileptogenesis and triggers long-term changes in hippocampal CA1 cells, in the fully kindled state. Eur. J. Neurosci. 11:1999;889-898.
48. Kawata M., Kazunari Y., Ozawa H., Nishi M., Ito T., Hu Z., Lu H., Yoshida M. Steroid hormones and their receptors in the brain. J. Ster. Biochem. Mol. Biol. 65:1998;273-280.
49. Kerrigan J.F., Shields W.D., Nelson T.Y., Bluestone D.L., Dodson W.E., Bourgeois B.F., Pellock J.M., Morton L.D., Monaghan E.P. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res. 42:2000;133-139.
50. Kling M.A., Smith M.A., Glowa J.R., Pluznik D., Demas J., deBellis M.D., Gold P.W., Schulkin J. Facilitation of cocaine kindling by glucocorticoids in rats. Brain Res. 629:1993;163-166.
51. Koenig J.I. Estrogen and brain function. Trends Endocrinol. Metab. 12:2001;4-6.
52. Kokate T.G., Svensson B.E., Rogawski M.A. Anticonvulsant activity of neurosteroids: Correlation with γ-aminobutyric acid-evoked chloride current potentiation. J. Pharmacol. Exp. Ther. 270:1994;1223-1229.
53. Kokate T.G., Yamaguchi S., Pannell L.K., Rajamani U., Carroll D.M., Grossman A.B., Rogawski M.A. Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice. J. Pharmacol. Exp. Ther. 287:1998;553-558.
54. Kokate T.G., Banks M.K., Magee T., Yamaguchi S., Rogawski M.A. Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J. Pharmacol. Exp. Ther. 288:1999;679-684.
55. Lacroix C., Fiett J., Benais J.-P., Gueux B., Bonete R., Villette J.-M., Gourmel B., Dreux C. Simultaneous radioimmunoassay of progesterone, androst-4-enedione, pregnenolone, dehydroepiandrosterone and 17-hydroxyprogesterone in specific regions of human brain. J. Ster. Biochem. 28:1987;317-325.
56. A receptor function. Trends Pharmacol. Sci. 16:1995;295-303.
57. Landgren S., Aasly J., Bäckström T., Dubrovsky B., Danielsson E. The effect of progesterone and its metabolites on the interictal epileptiform discharge in the cat's cerebral cortex. Acta Physiol. Scand. 131:1987;33-42.
58. Lanthier A., Patwardhan V.V. Sex steroids and 5-en-3β-hydroxysteroids in specific regions of human brain and cranial nerves. J. Ster. Biochem. 25:1986;445-449.
59. Laxer K., Blum D., Abou-Khalil B.W., Morrell M.J., Lee D.A., Data J.L., Monaghan E.P. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. Epilepsia. 41:2000;1187-1194.
60. Lephart E.D. Brain 5α-reductase: Cellular, enzymatic, and molecular perspectives and implications for biological function. Mol. Cell. Neurosci. 4:1993;473-484.
61. Liptakova S., Velisek L., Veliskova J., Moshe S.L. Effect of ganaxolone on furothyl seizures in developing rats. Epilepsia. 41:2000;788-793.
62. Logothetis J., Harner R. Electrocortical activation by estrogens. Arch. Neurol. 3:1960;290-297.
63. Logothetis J., Harner R., Morrell F., Torres F. The role of estrogens in catamenial exacerbation of epilepsy. Neurology. 9:1959;352-360.
64. A receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38:1992;379-395.
65. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 232:1986;1004-1007.
66. Marshall F.H., Stratton S.C., Mullings J., Ford E., Worton S.P., Oakley N.R., Hagan R.M. Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure. Pharmacol. Biochem. Behav. 58:1997;1-8.
67. McEwen B.S., Alves S.E., Bulloch K., Weiland N.G. Ovarian steroids and the brain: implications for cognition and aging. Neurology. 48:(7):1997;S8-S15.
68. Mellon S.H. Neurosteroids: Biochemistry, modes of action, and clinical relevance. J. Clin. Endocrinol. Metab. 78:1994;1003-1008.
69. Mensah-Nyagan A., Do-Rego J.L., Beaujean D., Luu-The V., Pelletier G., Vaudry H. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol. Rev. 51:1999;63-81.
70. Monaghan E.P., Navalta L.A., Shum L., Ashbrook D., Lee D.A. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia. 38:1997a;1026-1031.
71. Monaghan E.P., Harris S., Blum D., Morell M., Beydoun A., Abou-Khalil B.W., Moore J.L., McAuley J.W., Faught R.E., Laxer K., Marks W., Bergey G., Ko D., Lee D.A., Data J.L. Ganaxolone in the treatment of complex partial seizures: a double-blind presurgical design. Epilepsia. 38:(8):1997b;S179.
72. Morrell M.J. Hormones and epilepsy through the lifetime. Epilepsia. 33:(4):1992;S49-S61.
73. Morrell M.J. Epilepsy in women: the science of why it is special. Neurology. 53:(1):1999;S42-S48.
74. Murphy D.D., Segal M. Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones. J. Neurosci. 16:1996;4059-4068.
75. Murphy D.D., Segal M. Progesterone prevents estradiol-induced dendritic spine formation in cultured hippocampal neurons. Neuroendocrinology. 72:2000;133-143.
76. Murphy D.D., Cole N.B., Greenberger V., Segal M. Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J. Neurosci. 18:1998;2550-2559.
77. Orchinik M., Murray T.F., Franklin P.H., Moore F.L. Guanyl nucleotides modulate binding to steroid receptors in neuronal membranes. Proc. Natl. Acad. Sci. USA. 89:1992;3830-3834.
78. Paul S.M., Purdy R.H. Neuroactive steroids. FASEB J. 6:1992;2311-2322.
79. Penovich P.E. The effects of epilepsy and its treatment on sexual and reproductive function. Epilepsia. 41:(2):2000;S53-S61.
80. Reddy D.S., Rogawski M.A. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J. Pharmacol. Exp. Ther. 294:2000a;909-915.
81. Reddy D.S., Rogawski M.A. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol. Exp. Ther. 295:2000b;1241-1248.
82. Reid B.A., Gangar K.F. Catamenial epilepsy and gosorelin (letter). Lancet. 339:1992;253.
83. Roberts A.J., Keith L.D. Corticosteroids enhance convulsion susceptibility via central mineralocorticoid receptors. Psychoneuroendocrinology. 20:1995;891-902.
84. Rupprecht R., Holsboer F. Neuroactive steroids: mechanism of action and neuropsychopharmacological perspectives. Trends Neurosci. 22:1999a;410-416.
85. Rupprecht R., Holsboer F. Neuropsychopharmacological properties of neuroactive steroids. Steroids. 64:1999b;83-91.
86. Rupprecht R., Reul J.M.H.M., Trapp T., van Steensel B., Wetzel C., Damm K., Zieglgänsberger W., Holsboer F. Progesterone receptor-mediated effects of neuroactive steroids. Neuron. 11:1993;523-530.
87. Schumacher M., Guennoun R., Robel P., Baulieu E.E. Neurosteroids in the hippocampus: Neuronal plasticity and memory. Stress. 21:1997;65-78.
88. Schumacher M., Coirini H., Robert F., Guennoun R., El-Etr M. Genomic and membrane actions of progesterone: implications for reproductive physiology and behaviour. Behav. Brain Res. 105:1999;37-52.
89. Schwartz-Giblin S., Korotzer A., Pfaff D.W. Steroid hormone effects on picrotoxin-induced seizures in female and male rats. Brain Res. 476:1989;240-247.
90. Schwartzkroin P.A., McIntyre D.C. Limbic anatomy and physiology. Engel J. Jr, Pedley T.A. Epilepsy: A Comprehensive Textbook. 1997;323-340 Lippincott Raven, Philadelphia.
91. Selye H. The anesthetic effect of steroid hormones. Proc. Soc. Exp. Biol. Med. 46:1941;116-121.
92. Shields W.D., Kerrigan J.F., Bluestone D.L., Nelson T.Y., Wilner A.N., Dodson W.E., Bourgeois B.F.D., Pellock J.M., Morton L.D., Densel M.B., Lee D.A., Monaghan E.P. Ganaxolone in the treatment of refractory infantile spasms. Ann. Neurol. 42:1997;503-504.
93. Shughrue P.J., Merchenthaler I. Estrogen is more than just a 'sex hormone': Novel sites for estrogen action in the hippocampus and cerebral cortex. Front. Neuroendocrinol. 21:2000;95-101.
94. Shumate M.D., Lin D.D., Gibbs J.W. III, Holloway K.L., Coulter D.A. GABA(A) receptor function in epileptic human dentate granule cells: comparison to epileptic and control rat. Epilepsy Res. 32:1998;114-128.
95. Smith S.S. Estradiol administration increases neuronal responses to excitatory amino acids as a long term effect. Brain Res. 503:1989;354-357.
96. Smith S.S., Waterhouse B.D., Woodward D.J. Locally applied estrogens potentiate glutamate-evoked excitation of cerebellar Purkinje cells. Brain Res. 475:1988;272-282.
97. Steckelbroeck S., Heidrich D.D., Stoffel-Wagner B., Hans V.H.J., Schramm J., Bidlingmaier F., Klingmüller D. Characterization of aromatase cytochrome P450 activity in the human temporal lobe. J. Clin. Endocrinol. Metab. 84:1999a;2795-2801.
98. Steckelbroeck S., Stoffel-Wagner B., Reichelt R., Schramm J., Bidlingmaier F., Siekmann L., Klingmüller D. Characterization of 17β-hydroxysteroid dehydrogenase activity in brain tissue: testosterone formation in the human temporal lobe. J. Neuroendocrinol. 11:1999b;457-464.
99. Stitt S.L., Kinnard W.J. The effect of certain progestins and estrogens on the threshold of electrically induced seizure patterns. Neurology. 18:1968;213-216.
100. Stoffel-Wagner B., Watzka M., Steckelbroeck S., Wickert L., Schramm J., Romalo G., Klingmüller D., Schweikert H.U. Expression of 5α-reductase in the human temporal lobe of children and adults. J. Clin. Endocrinol. Metab. 83:1998a;3636-3642.
101. Stoffel-Wagner B., Watzka M., Steckelbroeck S., Schwaab R., Schramm J., Bidlingmaier F., Klingmüller D. Expression of CYP19 (aromatase) mRNA in the human temporal lobe. Biochem. Biophys. Res. Commun. 244:1998b;768-771.
102. Stoffel-Wagner B., Watzka M., Steckelbroeck S., Schramm J., Bidlingmaier F., Klingmüller D. Expression of 17β-hydroxysteroid dehydrogenase types 1, 2, 3 and 4 in the human temporal lobe. J. Endocrinol. 160:1999a;119-126.
103. Stoffel-Wagner B., Watzka M., Schramm J., Bidlingmaier F., Klingmüller D. Expression of CYP19 (aromatase) mRNA in different areas of the human brain. J. Steroid Biochem. Mol. Biol. 70:1999b;237-241.
104. Stoffel-Wagner B., Beyenburg S., Watzka M., Blümcke I., Bauer J., Schramm J., Bidlingmaier F., Elger C.E. Expression of 5α-reductase and 3α-hydroxisteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy. Epilepsia. 41:2000;140-147.
105. Thomas J., McLean J.H. Castration alters susceptibility of male rats to specific seizures. Physiol. Behav. 49:1991;1177-1179.
106. Tohgi H., Utsugisawa K., Yamagata M., Yoshimura M. Effects of age on messenger RNA expression of glucocorticoid, thyroid hormone, androgen, and estrogen receptors in postmortem human hippocampus. Brain Res. 700:1995;245-253.
107. Tsutsui K., Ukena K., Usui M., Sakamoto H., Takase M. Novel brain function: biosynthesis and action of neurosteroids in neurons. Neurosci. Res. 36:2000;261-273.
108. Waibel-Treber S., Minne H.W., Scharla S.H., Bremen T., Ziegler R., Leyendecker G. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma. Hum. Reprod. 4:1989;384-388.
109. Watzka M., Bidlingmaier F., Schramm J., Klingmüller D., Stoffel-Wagner B. Sex- and age-specific differences in human brain CYP11A1 mRNA expression. J. Neuroendocrinol. 11:1999;901-905.
110. Watzka M., Beyenburg S., Blümcke I., Elger C.E., Bidlingmaier F., Stoffel-Wagner B. Expression of mineralocorticoid and glucocorticoid receptor mRNA in the human hippocampus. Neurosci. Lett. 290:2000a;121-124.
111. Watzka M., Bidlingmaier F., Beyenburg S., Henke R.T., Clusmann H., Elger C.E., Schramm J., Klingmüller D., Stoffel-Wagner B. Corticosteroid receptor mRNA expression in the brains of patients with epilepsy. Steroids. 65:2000b;895-901.
112. Wieland S., Belluzzi J., Hawkinson J., Hogenkamp D., Upasani R., Stein L., Wood P.L., Gee K.W., Lan N.C. Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593. Psychopharmacology. 134:1997;46-54.
113. Woolley C.S. Effects of estrogen in the CNS. Curr. Opin. Neurobiol. 9:1999;349-354.
114. Woolley C.S. Estradiol facilitates kainic acid-induced, but not flurothyl-induced, behavioral seizure activity in adult female rats. Epilepsia. 41:2000;510-515.
115. Woolley C.S., McEwen B.S. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J. Comp. Neurol. 336:1993;293-306.
116. Woolley C.S., Schwartzkroin P.A. Hormonal effects on the brain. Epilepsia. 39:(8):1998;S2-S8.
117. Woolley C.S., Wenzel H.J., Schwartzkroin P.A. Estradiol increases the frequency of multiple synapse boutons in the hippocampal CA1 region of the adult female rat. J. Comp. Neurol. 373:1996;108-117.
118. Zahn C. Catamenial epilepsy: clinical aspects. Neurology. 53:(1):1999;S34-S37.
119. Zinder O., Dar D.E. Neuroactive steroids: their mechanism of action and their function in the stress response. Acta Physiol. Scand. 167:1999;181-188.